Company: EDSA
Filing Date: 2025-02-14
Form Type: 10-Q
Source: 0001171843-25-000866
Chunk: 38

Company: Edesa Biotech, Inc.
Filing Date: 2025-02-14
Form: 10-Q
Item: Part I, Item 1
Chunk 38
---
648
			)
			 
			$
			(52,418,968
			)
			 
			$
			7,048,800

			Issuance of common shares

			89,249

			315,201

			-

			-

			-

			-

			315,201

			Issuance costs

			-

			(24,457
			)

			-

			-

			-

			-

			(24,457
			)

			Share-based compensation

			-

			-

			-

			184,357

			-

			-

			184,357

			Net loss and comprehensive loss

			-

			-

			-

			-

			(572
			)

			(1,678,451
			)

			(1,679,023
			)

			Balance - December 31, 2023

			3,164,722

			$
			46,933,895

			$
			-

			$
			13,223,622

			$
			(215,220
			)
			 
			$
			(54,097,419
			)
			 
			$
			5,844,878

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

6

Edesa Biotech, Inc.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited)

1. Nature of Operations

Edesa Biotech, Inc. (the “Company” or “Edesa”) is a biopharmaceutical company focused on acquiring, developing and commercializing clinical stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. The Company is organized under the laws of British Columbia, Canada and is headquartered in Markham, Ontario. It operates under its wholly owned subsidiaries, Edesa Biotech Research, Inc., an Ontario, Canada corporation, and Edesa Biotech USA, Inc., a California, USA corporation.

The Company’s common shares trade on The Nasdaq Capital Market in the United States under the symbol “EDSA”.

Going Concern

These unaudited condensed consolidated financial statements have been prepared on a going concern basis which presumes the realization of assets and the discharge of liabilities in the normal course of operations for at least the